AU2021367976A1 - Deuterated aminothiazole compounds as antiviral compounds - Google Patents

Deuterated aminothiazole compounds as antiviral compounds Download PDF

Info

Publication number
AU2021367976A1
AU2021367976A1 AU2021367976A AU2021367976A AU2021367976A1 AU 2021367976 A1 AU2021367976 A1 AU 2021367976A1 AU 2021367976 A AU2021367976 A AU 2021367976A AU 2021367976 A AU2021367976 A AU 2021367976A AU 2021367976 A1 AU2021367976 A1 AU 2021367976A1
Authority
AU
Australia
Prior art keywords
alkyl
deuterium
herpes
compounds
ore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021367976A
Other languages
English (en)
Other versions
AU2021367976A9 (en
Inventor
Christian Gege
Gerald Kleymann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovative Molecules GmbH
Original Assignee
Innovative Molecules GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules GmbH filed Critical Innovative Molecules GmbH
Publication of AU2021367976A1 publication Critical patent/AU2021367976A1/en
Publication of AU2021367976A9 publication Critical patent/AU2021367976A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2021367976A 2020-10-29 2021-10-28 Deuterated aminothiazole compounds as antiviral compounds Pending AU2021367976A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20204545.6 2020-10-29
EP20204545 2020-10-29
PCT/EP2021/080023 WO2022090409A1 (en) 2020-10-29 2021-10-28 Deuterated aminothiazole compounds as antiviral compounds

Publications (2)

Publication Number Publication Date
AU2021367976A1 true AU2021367976A1 (en) 2023-06-08
AU2021367976A9 AU2021367976A9 (en) 2025-03-13

Family

ID=73037895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021367976A Pending AU2021367976A1 (en) 2020-10-29 2021-10-28 Deuterated aminothiazole compounds as antiviral compounds

Country Status (9)

Country Link
US (1) US12552756B2 (enExample)
EP (1) EP4237414A1 (enExample)
JP (1) JP2023552274A (enExample)
KR (1) KR20230131177A (enExample)
CN (1) CN116783171A (enExample)
AU (1) AU2021367976A1 (enExample)
CA (1) CA3196645A1 (enExample)
MX (1) MX2023004955A (enExample)
WO (1) WO2022090409A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4466255A1 (en) 2022-01-17 2024-11-27 Innovative Molecules GmbH Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2026078039A1 (en) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Oral administration forms of antiviral helicase-primase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
GEP20207128B (en) * 2016-04-06 2020-07-10 Molecules Gm Innovative Aminothiazole derivatives useful as antiviral agents
MX2020003369A (es) * 2017-10-05 2020-07-29 Innovative Molecules Gmbh Enantiomeros de tiazoles sustituidos como compuestos antivirales.
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑

Also Published As

Publication number Publication date
CN116783171A (zh) 2023-09-19
AU2021367976A9 (en) 2025-03-13
EP4237414A1 (en) 2023-09-06
KR20230131177A (ko) 2023-09-12
US20230391738A1 (en) 2023-12-07
MX2023004955A (es) 2023-05-17
WO2022090409A1 (en) 2022-05-05
US12552756B2 (en) 2026-02-17
JP2023552274A (ja) 2023-12-15
CA3196645A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CN110177788B (zh) 作为bcl-2选择性凋亡诱导剂的化合物
US12295945B2 (en) Enantiomers of substituted thiazoles as antiviral compounds
US12514858B2 (en) CD38 inhibitors
CN110546151B (zh) 凋亡诱导剂
US12552756B2 (en) Deuterated aminothiazole compounds as antiviral compounds
CA2782720A1 (en) Pyrrolo[2,3-d]pyrimidine compounds
JP2025502300A (ja) ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法
WO2021115335A1 (zh) 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
KR102874188B1 (ko) 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도
CN109843879A (zh) 作为dyrk1抑制剂的苯并噻唑衍生物
CN110483487B (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
US20160368944A1 (en) Linked purine pterin hppk inhibitors useful as antibacterial agents
WO2022262784A1 (zh) Idh突变体抑制剂及其用途
WO2023010078A9 (en) Muscarinic receptor 4 antagonists and methods of use
TW201811792A (zh) 作爲激酶抑制劑的取代的吡咯并[2,3-d]噠嗪-4-酮和吡唑并[3,4-d]噠嗪-4-酮
WO2026035901A1 (en) Tricyclic compounds for treatment of hsv
CN118556045A (zh) 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法
WO2026035900A1 (en) Tricyclic compounds for treatment of hsv
CN113015736A (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Legal Events

Date Code Title Description
SREP Specification republished